SEQENS. A new name for a global leader in pharmaceutical synthesis and specialty ingredients.

Novacap and all its activities unify their names into a new one and become SEQENS. 

SEQENS is an integrated global leader in pharmaceutical synthesis and specialty ingredients, delivering unrivalled market responsiveness and tailor-made solutions to our customers.  

SEQENS operates 24 manufacturing plants and 3 R&D centers in Europe, North America and Asia with 3,200 employees. More than 300 scientists, engineers and experts develop tailor-made solutions for our customers and ensure that products are successfully transferred into production. 

SEQENS. The Continuum of Progress

“As SEQENS, we intend to stand as a strong, global and integrated player in pharmaceutical synthesis and specialty ingredients. Our mission is to bring R&D and industrial performance to our clients’ projects. From now on, we want to better leverage on our strong expertise to develop and produce highly complex molecules with unique skills and the largest continuum of technologies available on the market.  

I am proud of what we have achieved so far, on behalf of SEQENS’ 3,200 scientists, engineers, and experts working across a range of fields such as QHSE, industrial methods and processes, quality, sales and marketing, finance, innovation, legal and more,” says Pierre Luzeau, SEQENS CEO.